<DOC>
	<DOCNO>NCT01266512</DOCNO>
	<brief_summary>Primary Objective : - Response rate ( contrast CT scan ) Secondary Objectives : - Progression-free survival ( PFS ) - Overall survival ( OS )</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy ( IMRT ) &amp; Docetaxel-cisplatin ( Carboplatin ) Followed Adjuvant Chemotherapy Inoperable Stage III Non-small-cell Lung Cancer</brief_title>
	<detailed_description>The duration study patient include 6-week screening phase , 12 week treatment phase ( include rest period 2 week ) follow long-term follow-up .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Pathologically prove locally advanced , inoperable , confirm PET scan ( thorax/ upper abdomen ) International stage III ( 2009 ) NSCLC without multifocal tumour lung Disease volume encompassible within tolerable Planning Target Volume treat 66 Gy FEV1 ( Force Expiratory Volume 1 Second ) &gt; 1000 ml Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin ≥ 1.5 time upper limit normal ALT ( Alanine Aminotransferase ) AST ( Aspartate transaminase ) ≤ 2.5 x upper limit normal ( ≤ 5 x upper limit normal patient liver derangement ) ECOG ( Eastern Cooperative Oncology Group ) PS 01 Exclusion criterion : Previous treatment chest radiotherapy , chemotherapy molecularly target agent Inadequate lung function ( Exercise tolerance le 1 FOS/Fight stair , FEV1 &lt; 1 L/sec , raise pCO2 ) History hypersensitivity contraindication study drug premedications product formulate polysorbate 80 Pregnant breastfeed woman , woman childbearing potential follow effective method contraception and/or unwilling unable test pregnancy ( either serum urine pregnancy test study entry Participation clinical trial investigational drug use within 30 day prior study entry The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>